Trial Profile
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Immediate and Modified Release Formulations of Orally Administered Solabegron in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Apr 2019
Price :
$35
*
At a glance
- Drugs Solabegron (Primary)
- Indications Irritable bowel syndrome; Overactive bladder
- Focus Pharmacokinetics
- Sponsors Velicept Therapeutics
- 23 Apr 2019 Status changed from recruiting to completed.
- 30 Apr 2018 Planned End Date changed from 1 Nov 2016 to 1 Dec 2018.
- 30 Apr 2018 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2018.